Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide

Masamitsu Yanada, Shingo Yano, Heiwa Kanamori, Moritaka Gotoh, Nobuhiko Emi, Kyoko Watakabe, Mineo Kurokawa, Akinori Nishikawa, Takehiko Mori, Naoto Tomita, Makoto Murata, Hisako Hashimoto, Hideho Henzan, Yoshinobu Kanda, Masashi Sawa, Akio Kohno, Yoshiko Atsuta, Tatsuo Ichinohe, Akiyoshi Takami

研究成果: Article

5 引用 (Scopus)

抄録

We conducted a retrospective registry-based study involving 198 patients with acute promyelocytic leukemia (APL) who underwent autologous hematopoietic cell transplantation (HCT) during second complete remission (CR2) from 1995 to 2012. Arsenic trioxide (ATO) became commercially available in Japan in December 2004, and a substantial increase in the annual numbers of transplantations has occurred since 2005. Patients transplanted after 2006 had significantly better relapse-free and overall survival than those transplanted before 2004 (p = .028 and p = .027, respectively). There was a significant difference in cumulative incidence of relapse in favor of those transplanted after 2006 (p = .008), whereas non-relapse mortality did not differ between the two groups (p = .683). Our findings suggest that the introduction of ATO may have reduced post-transplantation relapse without increasing non-relapse mortality, resulting in significant improvements in overall outcomes for relapsed APL patients undergoing autologous HCT during CR2.

元の言語English
ページ(範囲)1-7
ページ数7
ジャーナルLeukemia and Lymphoma
DOI
出版物ステータスAccepted/In press - 2016 10 4

Fingerprint

Acute Promyelocytic Leukemia
Cell Transplantation
Recurrence
Transplantation
Mortality
Registries
Japan
Survival
Incidence
arsenic trioxide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

これを引用

Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission : outcomes before and after the introduction of arsenic trioxide. / Yanada, Masamitsu; Yano, Shingo; Kanamori, Heiwa; Gotoh, Moritaka; Emi, Nobuhiko; Watakabe, Kyoko; Kurokawa, Mineo; Nishikawa, Akinori; Mori, Takehiko; Tomita, Naoto; Murata, Makoto; Hashimoto, Hisako; Henzan, Hideho; Kanda, Yoshinobu; Sawa, Masashi; Kohno, Akio; Atsuta, Yoshiko; Ichinohe, Tatsuo; Takami, Akiyoshi.

:: Leukemia and Lymphoma, 04.10.2016, p. 1-7.

研究成果: Article

Yanada, M, Yano, S, Kanamori, H, Gotoh, M, Emi, N, Watakabe, K, Kurokawa, M, Nishikawa, A, Mori, T, Tomita, N, Murata, M, Hashimoto, H, Henzan, H, Kanda, Y, Sawa, M, Kohno, A, Atsuta, Y, Ichinohe, T & Takami, A 2016, 'Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide', Leukemia and Lymphoma, pp. 1-7. https://doi.org/10.1080/10428194.2016.1231406
Yanada, Masamitsu ; Yano, Shingo ; Kanamori, Heiwa ; Gotoh, Moritaka ; Emi, Nobuhiko ; Watakabe, Kyoko ; Kurokawa, Mineo ; Nishikawa, Akinori ; Mori, Takehiko ; Tomita, Naoto ; Murata, Makoto ; Hashimoto, Hisako ; Henzan, Hideho ; Kanda, Yoshinobu ; Sawa, Masashi ; Kohno, Akio ; Atsuta, Yoshiko ; Ichinohe, Tatsuo ; Takami, Akiyoshi. / Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission : outcomes before and after the introduction of arsenic trioxide. :: Leukemia and Lymphoma. 2016 ; pp. 1-7.
@article{d681c542b1334ef78075a0e2574b1c17,
title = "Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide",
abstract = "We conducted a retrospective registry-based study involving 198 patients with acute promyelocytic leukemia (APL) who underwent autologous hematopoietic cell transplantation (HCT) during second complete remission (CR2) from 1995 to 2012. Arsenic trioxide (ATO) became commercially available in Japan in December 2004, and a substantial increase in the annual numbers of transplantations has occurred since 2005. Patients transplanted after 2006 had significantly better relapse-free and overall survival than those transplanted before 2004 (p = .028 and p = .027, respectively). There was a significant difference in cumulative incidence of relapse in favor of those transplanted after 2006 (p = .008), whereas non-relapse mortality did not differ between the two groups (p = .683). Our findings suggest that the introduction of ATO may have reduced post-transplantation relapse without increasing non-relapse mortality, resulting in significant improvements in overall outcomes for relapsed APL patients undergoing autologous HCT during CR2.",
keywords = "Acute promyelocytic leukemia, arsenic trioxide, autologous hematopoietic cell transplantation, second complete remission",
author = "Masamitsu Yanada and Shingo Yano and Heiwa Kanamori and Moritaka Gotoh and Nobuhiko Emi and Kyoko Watakabe and Mineo Kurokawa and Akinori Nishikawa and Takehiko Mori and Naoto Tomita and Makoto Murata and Hisako Hashimoto and Hideho Henzan and Yoshinobu Kanda and Masashi Sawa and Akio Kohno and Yoshiko Atsuta and Tatsuo Ichinohe and Akiyoshi Takami",
year = "2016",
month = "10",
day = "4",
doi = "10.1080/10428194.2016.1231406",
language = "English",
pages = "1--7",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission

T2 - outcomes before and after the introduction of arsenic trioxide

AU - Yanada, Masamitsu

AU - Yano, Shingo

AU - Kanamori, Heiwa

AU - Gotoh, Moritaka

AU - Emi, Nobuhiko

AU - Watakabe, Kyoko

AU - Kurokawa, Mineo

AU - Nishikawa, Akinori

AU - Mori, Takehiko

AU - Tomita, Naoto

AU - Murata, Makoto

AU - Hashimoto, Hisako

AU - Henzan, Hideho

AU - Kanda, Yoshinobu

AU - Sawa, Masashi

AU - Kohno, Akio

AU - Atsuta, Yoshiko

AU - Ichinohe, Tatsuo

AU - Takami, Akiyoshi

PY - 2016/10/4

Y1 - 2016/10/4

N2 - We conducted a retrospective registry-based study involving 198 patients with acute promyelocytic leukemia (APL) who underwent autologous hematopoietic cell transplantation (HCT) during second complete remission (CR2) from 1995 to 2012. Arsenic trioxide (ATO) became commercially available in Japan in December 2004, and a substantial increase in the annual numbers of transplantations has occurred since 2005. Patients transplanted after 2006 had significantly better relapse-free and overall survival than those transplanted before 2004 (p = .028 and p = .027, respectively). There was a significant difference in cumulative incidence of relapse in favor of those transplanted after 2006 (p = .008), whereas non-relapse mortality did not differ between the two groups (p = .683). Our findings suggest that the introduction of ATO may have reduced post-transplantation relapse without increasing non-relapse mortality, resulting in significant improvements in overall outcomes for relapsed APL patients undergoing autologous HCT during CR2.

AB - We conducted a retrospective registry-based study involving 198 patients with acute promyelocytic leukemia (APL) who underwent autologous hematopoietic cell transplantation (HCT) during second complete remission (CR2) from 1995 to 2012. Arsenic trioxide (ATO) became commercially available in Japan in December 2004, and a substantial increase in the annual numbers of transplantations has occurred since 2005. Patients transplanted after 2006 had significantly better relapse-free and overall survival than those transplanted before 2004 (p = .028 and p = .027, respectively). There was a significant difference in cumulative incidence of relapse in favor of those transplanted after 2006 (p = .008), whereas non-relapse mortality did not differ between the two groups (p = .683). Our findings suggest that the introduction of ATO may have reduced post-transplantation relapse without increasing non-relapse mortality, resulting in significant improvements in overall outcomes for relapsed APL patients undergoing autologous HCT during CR2.

KW - Acute promyelocytic leukemia

KW - arsenic trioxide

KW - autologous hematopoietic cell transplantation

KW - second complete remission

UR - http://www.scopus.com/inward/record.url?scp=84990199572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990199572&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1231406

DO - 10.1080/10428194.2016.1231406

M3 - Article

C2 - 27701911

AN - SCOPUS:84990199572

SP - 1

EP - 7

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -